A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a single-arm phase II trial of perifosine in renal cancer patients who have
experienced disease progression after receiving either sorafenib or sunitinib.